My passion is direct patient care that is comprehensive in treating the "whole patient" and family-centered by including children and their families in the development of the care plan. As a pediatric hospitalist, I provide care to hospitalized pediatric patients of all ages from infancy thru adolescence that are acutely ill or have medically complex conditions. This includes providing pediatric consultation to subspecialty and surgical patients and coordination of care among multiple provider teams.

Education of patients and their families as well as medical students, residents, and colleagues is a fundamental part of my patient care activities. I also have a specific interest in development of individualized care plans for patients with complex medical care needs.

Certified Specialties

Pediatric Hematology-Oncology - American Board of Pediatrics

Pediatrics - American Board of Pediatrics

Faculty Appointments

Professor (Part-Time) - Department of Pediatrics, Pediatric Hospitalist (SMD)

Credentials

Residency & Fellowship

Fellowship, Pediatrics, University of Rochester Medical Center. 1984 - 1987

Residency, Pediatrics, University of Massachusetts Medical Center. 1982 - 1984

Internship, Pediatrics, University of Massachusetts Medical Center. 1981 - 1982

Education

MD | University of Rochester School of Medicine/Dentistry (USA). 1981

Awards

Best Doctors in America. 2004 - 2014

Alpha Omega Alpha (AOA) Medical Honor Society. 2003 - 2010

George Washington Goler Associate Professor of Pediatrics. 2002 - 2005

Jacob Gitelman Award. 2002

Society of Pediatric Research. 1998

Research Fellow, Leukemia Society of America. 1987 - 1990

Wilmot Cancer Research Fellow. 1987 - 1990

Bradford Fellow. 1985 - 1986

Rochester Academy of Medicine OB-GYN Annual Award. 1980

Paul Gyorgy Annual Award, La Leche League International. 1980

Honor Society of Phi Beta Kappa. 1977

Honor Society of the Order of the Cross and Crown. 1977

Research

Dr. Asselin's research expertise is in clinical trials and clinical research to improve the care of patients with pediatric cancers. She serves as study investigator for two major international cooperative research groups, the Children's Oncology Group and the Dana-Farber Leukemia Consortium.

Through these groups she is actively involved in design and development of a number of studies of the treatment and biology of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Her specific areas of expertise are L-asparaginase pharmacology and immunology in treatment of ALL, treatment of T-cell disease (ALL and NHL), and the role of cardioprotection in prevention of cardiotoxocity in long-term survivors.

Publications

Journal Articles

Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study.

Rheingold SR, Bhojwani D, Ji L, Xu X, Devidas M, Kairalla JA, Shago M, Heerema NA, Carroll AJ, Breidenbach H, Borowitz M, Wood BL, Angiolillo AL, Asselin BL, Bowman WP, Brown P, Dreyer ZE, Dunsmore KP, Hilden JM, Larsen E, Maloney K, Matloub Y, Mattano LA, Winter SS, Gore L, Winick NJ, Carroll WL, Hunger SP, Raetz EA, Loh ML

Leukemia.. 2024 September 11 Epub 09/11/2024.

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.

Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho S, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH, Miles RR, Okada M, Patel S, Schafer ES, Schechter T, Shimano KA, Singh N, Steele A, Sulis ML, Vargas S, Winter SS, Wood C, Zweider-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, Allen CE

Blood.. 2024 May 16143 (20):2053-2058. Epub 1900 01 01.

Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer.

Chow EJ, Aggarwal S, Doody DR, Aplenc R, Armenian SH, Baker KS, Bhatia S, Blythe N, Colan SD, Constine LS, Freyer DR, Kopp LM, Laverdière C, Leisenring WM, Sasaki N, Vrooman LM, Asselin BL, Schwartz CL, Lipshultz SE

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2023 April 2041 (12):2248-2257. Epub 01/20/2023.

Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Dana-Farber Cancer Institute ALL Consortium trial 05-001.

Athale UH, Flamand Y, Blonquist T, Stevenson KE, Spira M, Asselin BL, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Harris MH, Neuberg DS, Sallan SE, Silverman LB

Pediatric blood & cancer.. 2022 August 69 (8):e29581. Epub 03/22/2022.

Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.

Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 July 140 (19):2106-2118. Epub 03/10/2022.

Cardiometabolic Risk in Childhood Cancer Survivors: A Report from the Children's Oncology Group.

Lipshultz ER, Chow EJ, Doody DR, Armenian SH, Asselin BL, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Schwartz CL, Lipshultz SE, Vrooman LM

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2022 March 131 (3):536-542. Epub 1900 01 01.

Late health outcomes after dexrazoxane treatment: A report from the Children's Oncology Group.

Chow EJ, Aplenc R, Vrooman LM, Doody DR, Huang YV, Aggarwal S, Armenian SH, Baker KS, Bhatia S, Constine LS, Freyer DR, Kopp LM, Leisenring WM, Asselin BL, Schwartz CL, Lipshultz SE

Cancer.. 2022 February 15128 (4):788-796. Epub 10/13/2021.

Corrigendum.

Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Weinberg OK, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn J, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB

Pediatric blood & cancer.. 2021 March 68 (3):e28885. Epub 12/31/2020.

Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001.

Burns MA, Place AE, Stevenson KE, Gutiérrez A, Forrest S, Pikman Y, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Gennarini LM, Kahn JM, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB

Pediatric blood & cancer.. 2021 January 68 (1):e28719. Epub 10/07/2020.

Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia.

Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Rabin KR, Zweidler-Mckay PA, Raetz EA, Loh ML, Schultz KR, Winick NJ, Carroll WL, Hunger SP

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 October 138 (28):3282-3293. Epub 08/19/2020.

Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort.

Ladas EJ, Blonquist TM, Puligandla M, Orjuela M, Stevenson K, Cole PD, Athale UH, Clavell LA, Leclerc JM, Laverdiere C, Michon B, Schorin MA, Greene Welch J, Asselin BL, Sallan SE, Silverman LB, Kelly KM

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 July 138 (19):2151-2159. Epub 04/24/2020.

Fluctuations in dietary intake during treatment for childhood leukemia: A report from the DALLT cohort.

Ladas EJ, Orjuela M, Stevenson K, Cole PD, Lin M, Athale UH, Clavell LA, Leclerc JM, Laverdiere C, Michon B, Schorin MA, Welch JG, Asselin BL, Sallan SE, Silverman LB, Kelly KM

Clinical nutrition : official journal of the European Society of Parenteral and Enteral Nutrition.. 2019 December 38 (6):2866-2874. Epub 01/03/2019.

Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization.

Winter SS, Dunsmore KP, Devidas M, Wood BL, Esiashvili N, Chen Z, Eisenberg N, Briegel N, Hayashi RJ, Gastier-Foster JM, Carroll AJ, Heerema NA, Asselin BL, Gaynon PS, Borowitz MJ, Loh ML, Rabin KR, Raetz EA, Zweidler-Mckay PA, Winick NJ, Carroll WL, Hunger SP

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2018 October 1036 (29):2926-2934. Epub 08/23/2018.

Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.

Athale UH, Puligandla M, Stevenson KE, Asselin B, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Harris MH, Neuberg DS, Sallan SE, Silverman LB

Pediatric blood & cancer.. 2018 October 65 (10):e27256. Epub 06/07/2018.

Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.

Vrooman LM, Blonquist TM, Harris MH, Stevenson KE, Place AE, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB

Blood advances.. 2018 June 262 (12):1449-1458. Epub 1900 01 01.

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.

Tran TH, Harris MH, Nguyen JV, Blonquist TM, Stevenson KE, Stonerock E, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Reshmi SC, Neuberg DS, Sallan SE, Loh ML, Silverman LB

Blood advances.. 2018 March 132 (5):529-533. Epub 1900 01 01.

Lack of Preparedness for Pediatric to Adult-Oriented Health Care Transition in Hospitalized Adolescents and Young Adults.

Dwyer-Matzky K, Blatt A, Asselin BL, Wood DL

Academic pediatrics.. 2018 18 (1):102-110. Epub 08/01/2017.

Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study.

Ladas EJ, Orjuela M, Stevenson K, Cole PD, Lin M, Athale UH, Clavell LA, Leclerc JM, Michon B, Schorin MA, Welch JG, Asselin BL, Sallan SE, Silverman LB, Kelly KM

Nutrition.. 2016 October 32 (10):1103-1109.e1. Epub 03/28/2016.

MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study.

Matlawska-Wasowska K, Kang H, Devidas M, Wen J, Harvey RC, Nickl CK, Ness SA, Rusch M, Li Y, Onozawa M, Martinez C, Wood BL, Asselin BL, Chen IM, Roberts KG, Baruchel A, Soulier J, Dombret H, Zhang J, Larson RS, Raetz EA, Carroll WL, Winick NJ, Aplan PD, Loh ML, Mullighan CG, Hunger SP, Heerema NA, Carroll AJ, Dunsmore KP, Winter SS

Leukemia.. 2016 September 30 (9):1909-12. Epub 03/08/2016.

A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.

Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, Heerema NA, Wood BL, Borowitz MJ, Burke MJ, Asselin BL, Devidas M, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE

Journal of pediatric hematology/oncology.. 2016 August 38 (6):409-17. Epub 1900 01 01.

Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.

Asselin B

Future oncology.. 2016 July 12 (13):1609-21. Epub 04/18/2016.

Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.

Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, Lipshultz SE

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 March 1034 (8):854-62. Epub 12/23/2015.

Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies.

Matloub Y, Stork L, Asselin B, Hunger SP, Borowitz M, Jones T, Bostrom B, Gastier-Foster JM, Heerema NA, Carroll A, Winick N, Carroll WL, Camitta B, Devidas M, Gaynon PS

Pediatric blood & cancer.. 2016 February 63 (2):255-61. Epub 10/20/2015.

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.

Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB

The Lancet. Oncology.. 2015 December 16 (16):1677-90. Epub 11/06/2015.

Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.

Chow EJ, Asselin BL, Schwartz CL, Doody DR, Leisenring WM, Aggarwal S, Baker KS, Bhatia S, Constine LS, Freyer DR, Lipshultz SE, Armenian SH

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2015 August 2033 (24):2639-45. Epub 05/26/2015.

Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.

Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP

Pediatric blood & cancer.. 2015 July 62 (7):1176-83. Epub 03/08/2015.

Clinical application of asparaginase activity levels following treatment with pegaspargase.

Bleyer A, Asselin BL, Koontz SE, Hunger SP

Pediatric blood & cancer.. 2015 June 62 (6):1102-5. Epub 11/12/2014.

Asparaginase pharmacokinetics and implications of therapeutic drug monitoring.doi: 10.3109/10428194.2014.1003056 [Epub ahead of print].

Asselin BL, Rizzari C.

Leuk Lymphoma. 2015; : 1-26.

Asparaginase pharmacokinetics and implications of therapeutic drug monitoring.

Asselin B, Rizzari C

Leukemia & lymphoma.. 2015 56 (8):2273-80. Epub 03/11/2015.

Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia.

Asselin BL, Fisher V

Clinical journal of oncology nursing.. 2014 December 18 (6):E107-12. Epub 1900 01 01.

Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.

Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP

Annals of the New York Academy of Sciences.. 2014 November 1329 :81-92. Epub 08/05/2014.

Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.

Tower RL, Jones TL, Camitta BM, Asselin BL, Bell BA, Chauvenet A, Devidas M, Halperin EC, Pullen J, Shuster JJ, Winick N, Kurtzberg J

Journal of pediatric hematology/oncology.. 2014 July 36 (5):353-61. Epub 1900 01 01.

Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: A report from the Children's Oncology Group.

Tower RL, Jones TL, Camitta BM, Asselin BL, Bell BA, Chauvenet A, Devidas M, Halperin EC, Pullen J, Shuster JJ, Winick N, and Kurtzberg J.

Journal of Pediatric Hematology/Oncology. 2014; 36(5): 353-61.

Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.

Salzer WL, Asselin BL, Plourde PV, Corn T, and Hunger SP.

Acad Sci. 2014; 1329(2014): 81-92.

Clinical application of asparaginase activity levels following treatment with pegaspargase.doi: 10.1002/pbc.25299. [Epub ahead of print]

Bleyer A, Asselin BL, Koontz SE, and Hunger SP.

Pediatr Blood Cancer. 2014; .

Impact of clinical and subclinical hypersensitivity to asparaginase in acute lymphoblastic leukemia. [Epub ahead of print] doi: 10.1188/14.CJON

Asselin BL, Fisher V.

Clin J Oncol Nurs. 2014; 18(6): E102-12.

Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion.

Asselin BL, Gaynon P, Whitlock JA

Current opinion in oncology.. 2013 December 25 Suppl 3 :S1-13; quiz S14-6. Epub 1900 01 01.

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.

Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS, Stevenson KE, Fleming MD, Sallan SE, Franco VI, Henkel JM, Asselin BL, Athale UH, Clavell LA, Michon B, Laverdiere C, Larsen E, Kelly KM, Silverman LB

Cancer.. 2013 October 1119 (19):3555-62. Epub 07/16/2013.

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP

Blood.. 2013 July 25122 (4):507-14. Epub 06/05/2013.

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdière C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, Silverman LB

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2013 March 2031 (9):1202-10. Epub 01/28/2013.

It's ALL in the liposomes: vincristine gets a new package.

Liesveld J, Asselin B

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2013 February 2031 (6):657-9. Epub 01/14/2013.

Therapeutic uses of high-dose omega-3 fatty acids to treat comatose patients with severe brain injury.

Sears B, Bailes J, Asselin B.

Pharma Nutrition. 2013; 1: 86-89.

Recent advances in acute lymphoblastic leukemia in children and adolescents: an expert panel discussion.

Asselin BL, Gaynon P, Whitlock JA.

Curr Opin Oncol. 2013; 25 Suppl, 3: S1-13; quiz S14-6.

It's all in the liposomes: Vincristine gets a new package.

Liesveld J, Asselin B.

J Clin Oncol Epub & J Clin Oncol. 2013; 31(6): 657-9.

Post-induction dexamethasone and individualized dosing of E. coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study, Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.

Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdiere C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, and Silverman LB.

J Clin Oncol Epub & J Clin Oncol. 2013; 31(9): 1202-10.

Erwinia asparaginase achieves therapeutic activity after PEG-asparaginase allergy: A report from the Children's Oncology Group.

Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, and Hunger SP.

Blood. 2013; 122(4): 507-14.

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.

Cancer. 2013; 119(19): 3555-62.

Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.

Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, Michon B, Laverdière C, Schorin MA, Larsen E, Usmani N, Sallan SE,

Pediatrics.. 2012 December 130 (6):1003-11. Epub 11/19/2012.

Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.

Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdière C, Michon B, Schorin MA, Sallan SE

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2012 April 130 (10):1042-9. Epub 02/27/2012.

The right dose for the right patient.

Asselin BL

Blood.. 2012 February 16119 (7):1617-8. Epub 1900 01 01.

Inside Blood: The right dose for the right patient.

Asselin BL.

Blood. 2012; 119(7): 1617-18.

Continuous versus bolus-infusion of doxorubicin in children with high-risk acute lymphoblastic leukemia: long-term cardiac outcomes.

Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, Michon B, Laverdiere C, Schorin MA, Larsen E, Usmani N, Sallan SE.

Pediatrics Epub & Pediatrics. 2012; 130(6): 1003-11.

Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: Associations with long-term echocardiographic outcomes.

Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdiere C, Michon B, Schorin MA, and Sallan SE.

J Clin Oncol. 2012; 30(10): 1042-9.

L-asparaginase for treatment of childhood acute lymphoblastic leukemia: what have we learned?

Asselin BL

Pediatric blood & cancer.. 2011 September 57 (3):357-8. Epub 04/20/2011.

Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).

Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, Lipshultz SE, Camitta BM

Blood.. 2011 July 28118 (4):874-83. Epub 04/07/2011.

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.

Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, Laverdière C, Michon B, Schorin M, Schwartz CL, Cohen HJ, Lipshultz SE, Silverman LB, Sallan SE

European journal of cancer : official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR).. 2011 June 47 (9):1373-9. Epub 04/20/2011.

Effectiveness of High Dose Methotrexate in T-cell Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Lymphoma: A Randomized Study by the Children's Oncology Group (POG 9404)

Asselin, BL; Devidas, M; Wang, C; Pullen, J; Borowitz, MJ; Hutchison, R; Lipshultz, S; Camitta, BM.

Blood. 2011; 118(4): 874-883.

L-Asparaginase for Treatment of Childhood Acute Lymphoblastic Leukemia: What Have We Learned?

Asselin, BL.

Pediatric Blood Cancer. 2011; 57(3): 357-358.

Late Cardiac Status in Long-Term Survivors of Childhood High-Risk Acute Lymphoblastic Leukemia 8 Years After Continuous or Bolus Infusion of Doxorubicin: The Dana-Farber Cancer Institute ALL 91-01 Randomized Trial

Lipshultz, SE; Miller, TL; Lipsitz, SR; Neuberg, DS; Dahlberg, SE; Colan, SD; Silverman, LB; Henkel, JM; Cushman, LL; Asselin, BL; Clavell, LA; Athale, U; Michon, B; Laverdiere, C; Schorin, MA; Larsen, E; Usmani, N; Sallan, SE, for the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium.

J Clin Oncol. 2011; .

Polyethylene glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: A Children's Oncology Group Study (POG 8866)

Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; and Camitta BM.

Journal of Pediatric Hematology Oncology. 2011; 33(8): 610-16.

The low incidence of secondary acute myelogenous leukemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukemia: A report from the Dana-Farber Cancer Institute ALL Consortium

Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, Laverdiere C, Michon B, Schorin M, Schwartz CL, Cohen HJ, Lipshultz SE, Silverman LB, and Sallan SE.

Eur J Cancer. 2011; 47: 1373-79.

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.

Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SD

The Lancet. Oncology.. 2010 October 11 (10):950-61. Epub 09/16/2010.

Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.

Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Laverdière C, Michon B, Schorin M, Schwartz CL, O'Brien JE, Cohen HJ, Sallan SE

Blood.. 2010 February 18115 (7):1351-3. Epub 12/10/2009.

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.

Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, Kelly KM, Laverdière C, Michon B, Schorin M, Cohen HJ, Sallan SE, Silverman LB

Pediatric blood & cancer.. 2010 February 54 (2):199-205. Epub 1900 01 01.

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).

Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O'Holleran EW, Neuberg DS, Cohen HJ, Sallan SE

Leukemia.. 2010 February 24 (2):320-34. Epub 12/17/2009.

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995)

Silverman, LB; Stevenson, K; O'Brien, JE; Asselin, BL; Athale, UH; Clavell, L; Cole, PD; Kelly, K; Laverdiere, C; Michon, B; Schorin, M; Schwartz, CL; Whyte, O'Holleran, E; Neuberg, DS; Cohen, HJ; Sallan, SE.

Leukemia. 2010; 24: 320-334.

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia: pharmacodynamics and tolerability.

Vrooman, LM; Supko, J; Neuberg, DS; Asselin, BL; Athale, UH, Clavell, L; Kelly, K; Laverdiere, C; Michon, B; Schorin, M; Sallan, SE; Silverman, LB.

Pediatric Blood and Cancer. 2010; 54: 199-205.

Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.

Silverman, LB; Supko, JG; Stevenson, KE; Woodward, C; Vrooman, LM; Neuberg, DS; Asselin, BL; Athale, UH; Cole, PD; Kelly, KM; Laverdiere, C; Michon, B; Schorin, M; Schwartz, CL; O'Brien, JE; Cohen HJ; Sallan, SE.

Blood. 2010; 115(7): 1351-53.

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukemia: long-term follow-up of a prospective, randomized, multicentre trial.

Lipshultz SE; Scully RE; Lipsitz SR; Sallan SE; Silverman LB; Miller TL; Barry EV; Asselin BL; Athale U; Clavell LA; Larsen E; Moghrabi A; Samson Y; Michon B; Schorin MA; Cohen HJ; Neuberg DS; Orav EJ; Colan SD.

Lancet Oncol. 2010; 11: 950-61.

Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.

Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Samson Y, Schorin MA, Cohen HJ, Lipshultz SE, Sallan SE, Silverman LB

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2008 March 126 (7):1106-11. Epub 1900 01 01.

Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.

Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Sanson Y, Schorin MA, Cohen HJ, Lipshultz SE, Sallan SE, and Silverman LB.

J Clin Oncol. 2008; 26(7): 1106-11.

Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Winter SS, Jiang Z, Khawaja HM, Griffin T, Devidas M, Asselin BL, Larson RS,

Blood.. 2007 September 1110 (5):1429-38. Epub 05/10/2007.

Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Salzer WL, Devidas M, Shuster JJ, Wang C, Chauvenet A, Asselin BL, Camitta BM, Kurtzberg J,

Journal of pediatric hematology/oncology.. 2007 June 29 (6):369-75. Epub 1900 01 01.

Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.

Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE, Silverman LB

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2007 March 125 (7):813-9. Epub 1900 01 01.

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.

Moghrabi A, Levy DE, Asselin BL, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelberg RD, Cohen HJ.

Blood First Edition Paper, prepublished online Sept 26, 2006. DOI 10.1182/blood-206-06-027714. 2007; 109(3): 896-904.

Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Salzer WL, Devias M, Shuster JJ, Wang C, Chauvenet A, Asselin BL, Camitta BM and Kurtzberg J.

J Pediatr Hematol/Oncol. 2007; 29(6): 369-375.

Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.

Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL.

Anticancer Res. 2007; 27(4C): 2561-72.

Favorable Outcome for Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI; Boston, MA) ALL Consortium Protocols.

Barry EV, Deangelo DJ, Neuberg DS, Loh MS, Asselin BL, Barr R, Clavell L, Hurwitz C, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE and Silverman LB.

Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007; 25(7): 813-9.

Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Winter SS, Jiang Z, Khawaja H, Griffin T, Devidas M, Asselin BL, and Larsen RS.

Blood. 2007; 110(5): 1429-38.

Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.

Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL

Anticancer research.. 2007 27 (4C):2561-72. Epub 1900 01 01.

Length of stay and mortality associated with febrile neutropenia among children with cancer.

Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2005 November 123 (31):7958-66. Epub 1900 01 01.

Length of stay and morbidity associated with febrile neutropenia among children with cancer.

Basu SK, Fernandez ID, Fisher SG, Asselin BL, and Lyman GH.

J Clin Oncol. 2005; 23(31): 7958-66.

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.

Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE

The New England journal of medicine.. 2004 July 8351 (2):145-53. Epub 1900 01 01.

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.

Lipshultz SE, Nader R, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr, RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD and Sallan SE.

N Engl J Med. 2004; 351(2): 145-53.

Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.

Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE, Asselin BL

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2003 October 121 (19):3616-22. Epub 1900 01 01.

Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment.

Dalton VK, Rue M, Silverman LB, Gelber RD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Tarbell NJ, Sallan SE, Cohen LE

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2003 August 121 (15):2953-60. Epub 1900 01 01.

Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment.

Dalton VK, Rue M, Silverman LB, Gelber RD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samaon Y, Schorin M, Tarbell NJ, Sallan SE, and Cohen LE.

J Clin Oncol. 2003; 21(15): 2953-60.

Childhood T-Cell Acute Lymphoblastic Leukemia (ALL): the Dana-Farber Cancer Institute ALL Consortium experience.

Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE and Asselin BL.

J Clin Oncol. 2003; 21(19): 3616-22.

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.

Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2002 March 1520 (6):1677-82. Epub 1900 01 01.

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.

LeClerc JM, Billett AL, Gelber RD, Dalton V, Tarbell N, Lipton JM, Barr R, Clavell LA, Asselin B, Hurwitz C, Schorin M, Lipshultz SE, Declerck L, Silverman LB, Cohen HJ, Sallan SE

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2002 January 120 (1):237-46. Epub 1900 01 01.

Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01

LeClerc JM, Billett AL, Gelber RD, Tarbell NJ, Lipton JM, Barr RD, Clavell LA, Asselin BL, Hurwitz CA, Schorin MA, Dalton VK, Declerck L, Cohen HJ and Sallan SE.

J Clin Oncol. 2002; 20(1): 237-46.

Doxorubicin administration by continuous infusion is not cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol

Lipshultz SE, Giantris AL, Lipsitz SR, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, and Colan SD.

J Clin Oncol. 2002; 20(6): 1677-82.

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE

Blood.. 2001 March 197 (5):1211-8. Epub 1900 01 01.

Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01.

Silverman LB, Gelber RD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Dalton VK, Zou G, Cohen HJ and Sallan SE.

Blood. 2001; 97(5): 1211-8.

Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995).

Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Lipton JM, Cohen HJ, Sallan SE

Leukemia.. 2000 December 14 (12):2247-56. Epub 1900 01 01.

Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia.

Asselin BL, Kreissman S, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD, Sallan SE, Cohen HJ

Journal of pediatric hematology/oncology.. 1999 21 (1):6-12. Epub 1900 01 01.

The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia.

Asselin BL

Advances in experimental medicine and biology.. 1999 457 :621-9. Epub 1900 01 01.

Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.

Graham ML, Asselin BL, Herndon JE, Casey JR, Chaffee S, Ciocci GH, Daeschner CW, Davis AR, Gold S, Halperin EC, Laughlin MJ, Martin PL, Olson JF, Kurtzberg J

Bone marrow transplantation.. 1998 May 21 (9):879-85. Epub 1900 01 01.

Anthracycline Induced Cardiotoxicity

Giantris A, Abdurrahman L, Hinkle A, Asselin BL, Lipshultz S.

Critical Reviews in Oncology-Hematology. 1998; 27: 53-68.

Toxicity, pharmacology and feasibility of administration of PEG-L-Asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia.

Graham ML, Asselin, BL, Herndon JE, III, Casey JR, Chaffee S. Ciocci GH, Daeschner CW, Davis AR, Gold S, Halperin EC, Laughlin MJ, Martin PL, Olson JF, and Kurtzberg J.

Bone Marrow Transplantation. 1998; 21(9): 879-85.

Magnetic resonance imaging appearance of fibromatosis colli.

Snitzer EL, Fultz PJ, Asselin B

Magnetic resonance imaging.. 1997 15 (7):869-71. Epub 1900 01 01.

Right atrial thrombi in children with cancer and indwelling catheters.

Korones DN, Buzzard CJ, Asselin BL, Harris JP

The Journal of pediatrics.. 1996 June 128 (6):841-6. Epub 1900 01 01.

Pegaspargase: A viewpoint

Asselin BL.

Clin Therapeutics. 1996; 5: 497-498.

Right atrial thrombi in children with cancer and indwelling catheters.

Korones DN, Buzzard CJ, Asselin BL and Harris JP.

Journal of Pediatrics. 1996; 128(6): 841-6.

Comparative pharmacokinetic studies of three asparaginase preparations.

Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 1993 September 11 (9):1780-6. Epub 1900 01 01.

Evaluation of tumor cell heterogeneity based on response to chemotherapy.

Asselin BL

Clinica chimica acta; international journal of clinical chemistry.. 1992 March 13206 (1-2):33-44. Epub 1900 01 01.

Application of the MTT assay to chemosensitivity testing using human leukemic cell lines

Stephens R, Asselin BL.

Journal Univ Rochester Medical Center. 1992; 3(2).

Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor.

Asselin BL, Lorenson MY, Whitin JC, Coppola DJ, Kende AS, Blakley RL, Cohen HJ

Cancer research.. 1991 December 1551 (24):6568-73. Epub 1900 01 01.

Clinical use of intravenous immunoglobulin

Asselin BL.

Hospital Therapy. 1990; 15(4): 479-439.

Clearance of L-asparaginase enzyme activity and protein

Rupp IP*, Asselin BL, Whitin JC, Cohen HJ.

Journal Univ Rochester Medical Center. 1990; 2(2): 2-5.

In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase.

Asselin BL, Ryan D, Frantz CN, Bernal SD, Leavitt P, Sallan SE, Cohen HJ

Cancer research.. 1989 August 149 (15):4363-8. Epub 1900 01 01.

Maternal disease as a consideration in lactation management.

Asselin BL, Lawrence RA

Clinics in perinatology.. 1987 March 14 (1):71-87. Epub 1900 01 01.

Books

Nelson Textbook of Pediatrics / 21st Edition (2020)

Chapter: "Epidemiology of Childhood and Adolescent Cancer:

Authors: Asselin BL

Publisher: WB Saunders, Philadelphia 2020

Nelson Textbook of Pediatrics / 20th Edition (2015)

Chapter: "Epidemiology of Childhood and Adolescent Cancer"

Authors: Asselin BL

Publisher: WB Saunders, Philadelphia 2015

Nelson Textbook of Pediatrics / 19th Edition (2011)

Chapter: "Epidemiology of Childhood and Adolescent Cancer"

Authors: Asselin BL

Publisher: WB Saunders, Philadelphia 2011

Textbook of Radiation Oncology (2010)

Chapter: Pediatric Leukemias and Lymphomas

Authors: Asselin, BL; Hudson, M; Constine, LS

Publisher: WB Saunders, Philadelphia 2010

Pediatric Clinical Advisor (2007)

Chapter: Histiocytosis Syndromes

Authors: Asselin BL.

Publisher: CV. Mosby, Inc, St. Louis, MO 2007

Pediatric Clinical Advisor (2007)

Chapter: Non-Hodgkin's Lymphoma

Authors: Asselin BL

Publisher: CV Mosby Inc., St. Louis, MO 2007

Principles and Practice of Radiation Oncology (2007)

Chapter: Lymphomas in Children

Authors: Hudson M, Asselin BL, Constine LS

Publisher: Lippincott, Williams and Wilkins, Inc., Philadelphia 2007

Principles and Practice of Radiation Oncology (2004)

Chapter: "Lymphomas in Children"

Authors: Hudson M, Asselin BL, Mandell LR, Constine LS

Publisher: Lippincott Williams & Wilkins, Philadelphia, PA 2004

Textbook of Radiation Oncology (2004)

Chapter: "Pediatric Leukemias and Lymphomas"

Authors: Asselin BL, Hudson M, Mandell L, Constine LS

Publisher: WB Saunders, Philadelphia, PA 2004

Treatment of Acute Leukemias: New Directions for Clinical Research (2003)

Chapter: "Asparaginase"

Authors: Asselin BL, Kurtzberg J

Publisher: The Humana Press, Inc. 2003

Primary Pediatric Care (2001)

Chapter: "The Leukemias of Childhood"

Authors: Asselin BL

Publisher: C.V. Mosby Co., St. Louis, MO 2001

Pediatric Clinical Advisor (2001)

Chapter: "Non-Hodgkin's Lymphoma"

Authors: Asselin BL

Publisher: C.V. Mosby, Inc., St. Louis, MO 2001

Leukemia: Perspectives on disease and illness (2000)

Authors: Peacock J; Asselin BL (medical consultant)

Publisher: Capstone Press, Mankato, MN 2000

Current Pediatric Therapy (1998)

Chapter: "Hemolytic Anemia in Children"

Authors: Asselin BL

Publisher: W.B. Saunders Co. 1998

Primary Pediatric Care (1997)

Chapter: "The Leukemias of Childhood"

Authors: Asselin BL

Publisher: C.V. Mosby Co., St. Louis, MO 1997

Acute Lymphoblastic Leukemia- The Cutting Edge (1997)

Chapter: "Laboratory Monitoring of Asparaginase Therapy"

Authors: Asselin BL

Publisher: Baylor-Sammons Cancer Center, Dallas, TX 1997

Acute Lymphoblastic Leukemia -The Cutting Edge (1997)

Chapter: "Treatment for Childhood Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Consortium Experience"

Authors: Silverman LB, Asselin BL, Sallan SE

Publisher: Baylor-Sammons Cancer Center, Dallas, TX 1997

Conn's Current Therapy (1994)

Chapter: "Nonimmune Hemolytic Anemia"

Authors: Asselin BL, Segel GB.

Publisher: W.B. Saunders Co. 1994

Primary Pediatric Care (1992)

Chapter: "The Leukemias of Childhood"

Authors: Asselin BL

Publisher: C.V. Mosby Co., St. Louis, MO 1992

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.